Genetic products differentially expressed in tumors and the use thereof
CA 3000243 C · Owner: Astellas Pharma Inc. · Inventors: Sahin, Ugur; Koslowski, Michael; Tureci, Ozlem
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. Said invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors proteins, polypeptides and peptides which are expressed in association with tumors,and to the nucleic coding acids for said polypeptides peptides and proteins.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 21, 2003 and granted January 3, 2023. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.